|
Eliseev M.S.
What we know about gout today
|
№1 / 2024
|
|
Gaydukova I.Z., Mazurov V.I., Inamova O.V., Zinserling A.Yu., Bashkinov R.A.
Increasing of glomeral filtration rate in the setting of serum uric acid normalization in high cardiovascular risk patients – clinical observations
|
№3 / 2023
|
|
Panevin T.S., Eliseev M.S., Bobkova A.O., Dimitreva A.E., Urumova M.M.
Use of dapagliflozin in a comorbid patient: new opportunities
|
№3 / 2023
|
|
Borovkova N.Yu., Kurashin V.K., Tokareva A.S., Makarova E.V., Nekrasov A.A., Savitskaya N.N., Mironov M.A.
Hyperuricemia and reduced glomerular filtration rate in the population among Nizhny Novgorod region inhabitants
|
№3 / 2023
|
|
Mazurov V.I., Bashkinov R.A., Inamova O.V., Petrova M.S., Morozova K.P.
Therapy of osteoarthritis in combination with asymptomatic hyperuricemia: results of a pilot study
|
№1 / 2023
|
|
Prometnaya G.A., Batyushin M.M., Bondarenko N.B.
Association of hyperuricemia with metabolism in patients with chronic kidney disease of 5th stage on hemodialysis
|
№3 / 2019
|
|
I.M. Marusenko, I.I. Polskaya, T.I. Kulagina, N.N. Vezikova
Metabolic syndrome in patients with gout and its impact on the risk of cardiovascular diseases
|
№3 / 2016
|
Русский
